tolperisone has been researched along with Spasm in 8 studies
Tolperisone: A centrally acting muscle relaxant that has been used for the symptomatic treatment of spasticity and muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1211)
Spasm: An involuntary contraction of a muscle or group of muscles. Spasms may involve SKELETAL MUSCLE or SMOOTH MUSCLE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tolperisone is a nonopioid, centrally acting muscle relaxant in clinical development in the USA for the treatment of symptoms associated with acute, painful muscles spasms of the back." | 9.51 | RESUME-1: a Phase III study of tolperisone in the treatment of painful, acute muscle spasms of the back. ( Kaye, R; Torres, K; Vaughan, SA, 2022) |
| "To generate real world clinical data on efficacy and tolerability of tolperisone 150 mg in painful muscle spasms in Indian population." | 9.15 | A phase IV observational multi-centre, open-label study on efficacy and safety of tolperisone 150 mg in patients with painful muscle spasm associated with degenerative or inflammatory diseases of the musculoskeletal system. ( Keny, S; Prabhoo, R; Prabhoo, T; Rana, R; Singh, A, 2011) |
| "The efficacy and safety of oral tolperisone hydrochloride (Mydocalm) in the treatment of painful reflex muscle spasm was assessed in a prospective, randomized, double-blind, placebo-controlled trial." | 9.08 | Efficacy and tolerance of repeated oral doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: results of a prospective placebo-controlled double-blind trial. ( Alken, RG; Pratzel, HG; Ramm, S, 1996) |
| "Tolperisone is a nonopioid, centrally acting muscle relaxant in clinical development in the USA for the treatment of symptoms associated with acute, painful muscles spasms of the back." | 5.51 | RESUME-1: a Phase III study of tolperisone in the treatment of painful, acute muscle spasms of the back. ( Kaye, R; Torres, K; Vaughan, SA, 2022) |
| "To generate real world clinical data on efficacy and tolerability of tolperisone 150 mg in painful muscle spasms in Indian population." | 5.15 | A phase IV observational multi-centre, open-label study on efficacy and safety of tolperisone 150 mg in patients with painful muscle spasm associated with degenerative or inflammatory diseases of the musculoskeletal system. ( Keny, S; Prabhoo, R; Prabhoo, T; Rana, R; Singh, A, 2011) |
| "The role of tolperisone hydrochloride, a centrally acting muscle relaxant in relieving painful muscle spasm is recently being discussed." | 5.10 | Prophylactic tolperisone for post-exercise muscle soreness causes reduced isometric force--a double-blind randomized crossover control study. ( Arendt-Nielsen, L; Bajaj, P; Madeleine, P; Svensson, P, 2003) |
| "The efficacy and safety of oral tolperisone hydrochloride (Mydocalm) in the treatment of painful reflex muscle spasm was assessed in a prospective, randomized, double-blind, placebo-controlled trial." | 5.08 | Efficacy and tolerance of repeated oral doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: results of a prospective placebo-controlled double-blind trial. ( Alken, RG; Pratzel, HG; Ramm, S, 1996) |
| "The high efficacy of mydocalm in the treatment of pain syndromes with the muscle spasm has been demonstrated." | 2.80 | [The results of the multicenter pharmaco-epidemiological observational project on the use of mydocalm in the treatment of pain syndromes with the muscle spasm]. ( Baliazin, VA; Barantsevich, ER; Belova, AN; Bogdanov, EI; Danilenko, OA; Gafurov, BG; Galanov, DV; Guekht, AB; Guseinov, SG; Khabirov, FA; Lebedeva, AV; Miakotnykh, VS; Mishchenko, TS; Musaev, SK; Prokopenko, SV; Shprakh, VV; Shyralieva, RK; Skoromets, AA; Spirin, NN; Toktomushev, CT; Volkova, LI, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Vaughan, SA | 1 |
| Torres, K | 1 |
| Kaye, R | 1 |
| Skoromets, AA | 1 |
| Guekht, AB | 1 |
| Galanov, DV | 1 |
| Danilenko, OA | 1 |
| Barantsevich, ER | 1 |
| Lebedeva, AV | 1 |
| Belova, AN | 1 |
| Shprakh, VV | 1 |
| Bogdanov, EI | 1 |
| Prokopenko, SV | 1 |
| Khabirov, FA | 1 |
| Spirin, NN | 1 |
| Baliazin, VA | 1 |
| Miakotnykh, VS | 1 |
| Volkova, LI | 1 |
| Gafurov, BG | 1 |
| Mishchenko, TS | 1 |
| Toktomushev, CT | 1 |
| Shyralieva, RK | 1 |
| Musaev, SK | 1 |
| Guseinov, SG | 1 |
| Prabhoo, R | 1 |
| Keny, S | 1 |
| Prabhoo, T | 1 |
| Singh, A | 1 |
| Rana, R | 1 |
| Glück, J | 1 |
| Rymarczyk, B | 1 |
| Rogala, B | 1 |
| Kocsis, P | 1 |
| Tarnawa, I | 1 |
| Kovács, G | 1 |
| Szombathelyi, Z | 1 |
| Farkas, S | 1 |
| Bajaj, P | 1 |
| Arendt-Nielsen, L | 1 |
| Madeleine, P | 1 |
| Svensson, P | 1 |
| Neverov, VA | 1 |
| Kurbanov, SKh | 1 |
| Pratzel, HG | 1 |
| Alken, RG | 1 |
| Ramm, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, 14-Day, Double-blind, Randomized, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Tolperisone in Subjects With Pain Due to Acute Back Muscle Spasm[NCT04671082] | Phase 3 | 1,004 participants (Actual) | Interventional | 2020-12-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 trials available for tolperisone and Spasm
| Article | Year |
|---|---|
RESUME-1: a Phase III study of tolperisone in the treatment of painful, acute muscle spasms of the back.
Topics: Back Pain; Female; Humans; Male; Muscle Relaxants, Central; Spasm; Tolperisone; Treatment Outcome | 2022 |
[The results of the multicenter pharmaco-epidemiological observational project on the use of mydocalm in the treatment of pain syndromes with the muscle spasm].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Male; Middle Aged; Muscle Relaxants, | 2015 |
A phase IV observational multi-centre, open-label study on efficacy and safety of tolperisone 150 mg in patients with painful muscle spasm associated with degenerative or inflammatory diseases of the musculoskeletal system.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Female; Humans; India; Male; Middle A | 2011 |
Prophylactic tolperisone for post-exercise muscle soreness causes reduced isometric force--a double-blind randomized crossover control study.
Topics: Adult; Cross-Over Studies; Double-Blind Method; Electromyography; Exercise; Humans; Isometric Contra | 2003 |
Efficacy and tolerance of repeated oral doses of tolperisone hydrochloride in the treatment of painful reflex muscle spasm: results of a prospective placebo-controlled double-blind trial.
Topics: Administration, Oral; Adult; Aged; Double-Blind Method; Humans; Middle Aged; Muscle Relaxants, Centr | 1996 |
3 other studies available for tolperisone and Spasm
| Article | Year |
|---|---|
An immediate hypersensitivity reaction caused by tolperisone hydrochloride.
Topics: Drug Hypersensitivity; Edema; Erythema; Humans; Lidocaine; Male; Middle Aged; Muscle Relaxants, Cent | 2011 |
[Mydeton: a centrally acting muscle relaxant drug from Gedeon Richter LTD].
Topics: Animals; Drug Industry; Humans; Hungary; Muscle Relaxants, Central; Sodium Channels; Spasm; Tolperis | 2002 |
[Restorative treatment of degenerative-dystrophic diseases of large joints].
Topics: Adult; Female; Humans; Joint Diseases; Male; Middle Aged; Muscle Relaxants, Central; Muscle, Skeleta | 2004 |